Leadership inspired by biotechology, health policy, and bioethics
At Cell Machines, people are not just names on a page, but involved, dedicated and experienced professionals committed to our mission of making affordable and available protein therapeutics.
James Kelly, PhD
Founding Partner, CEO and Chief Scientific Officer
Dr. Jim Kelly is the inventor and imagination behind Cell Machines’ basic technology. Dr. Kelly is a liver biologist trained at The Wistar Institute and Temple University. Jim is a former faculty member of Baylor College of Medicine, and has studied liver biology for his entire career. Dr. Kelly founded Cell Machines in 2011 with the expressed purpose of improving the design and production of high cost protein therapies and making them affordable globally.
He has also been a founder and senior executive in several Houston based startups including Hepatix, Inc., Amphioxus Cell Technologies, Inc., Stem Cell Innovations, Inc. and EGCell Scientific. At Hepatix and Stem Cell Innovations, he managed teams in both the US and Europe. He has overseen FDA sanctioned clinical trials, has several issued and pending patents, and has over 25 publications in peer reviewed journals. He has raised over $40 million in venture and investment capital for his various companies and has secured and overseen execution of contracts with a variety of large and small pharmaceutical/biotechnology companies such as Bayer, Aventis, Incyte and Promega. He holds a PhD in Biochemistry from Temple University, completed postdoctoral training at the Wistar Institute at the University of Pennsylvania and served on the faculty in the Pathology Department of the Baylor College of Medicine in Houston.
Thomas Campbell Jackson, BS MPH
Founding Partner and Advisor
Mr. Jackson is a cofounder of Cell Machines. He is a Venture Partner at Easton Capital Investment Group, a New York based firm focused on early stage life sciences companies. He is or has been a Director of Nanotronics Imaging, Imaginal Disc Productions, and other science and technology startups.
Mr. Jackson has consulted in health economics and policy for public and private clients, and for policy think tanks. He was Director of the City of New York’s Employee Health Benefits Program, administering health coverage for over a million city employees and retirees. He serves on the board of Overseers of Columbia University’s Mailman School of Public Health as well as the Board of its Alumni Association. He is a member of the Board of the Galen Institute, the Metanexus Institute, the Imagine Science Film Festival, and the Bellevue Literary Press, and formerly, of the New York Academy of Sciences. He is also a film producer, with several science-themed works to his credit.
Mr Jackson received a BA in Economics and German from Tufts University, studied Economics at the Eberhard Karls Universität Tübingen, Germany, and has an MPH in Health Policy and Management from Columbia University.
David Perryman, JD
David Perryman is patent counsel and advisor to Cell Machines. In addition, he is COO of DRIVE: Drug Innovation Ventures at Emory University. Mr. Perryman founded two other biotechnology companies, and was President, CEO and founder of Zirus. Mr. Perryman practiced biotechnology patent law for over 20 years at Needle & Rosenberg, delivering patent business strategies to biotech firms, venture funds, the CDC, NIH, FDA and numerous universities.
Mr. Perryman has served as a founder and special advisor to Georgia Venture Partners, a panelist at the Institute of Medicine’s Countermeasure/Bioterrorism policy meeting in 2010 and a featured presenter in 2010 at the 8th Annual BioDefense Summit. In 2014, Mr. Perryman received Georgia’s top award for contribution to the state’s biotechnology industry, the 2014 Industry Growth Award from GaBio.
All website photography is being used for illustrative purposes only, and any person depicted in the photography is a model.